News & Insights

New-research-into-in-vitro-strategies-for-demonstrating-bioequivalence-in-generic-nasal-sprays

Nanopharm Announce Appointment of Head of Device Development

NEWPORT, UK, December 7th, 2016 — Nanopharm Ltd (“Nanopharm”), a leading provider of tailored analytical and drug development services, with a focus on orally inhaled and nasal drug products (OINDPs), today announced the appointment of Arron Danson as Head of Device Development.

Arron has over 20 years of experience in the field of medical product development with a specific interest in pulmonary and nasal delivery devices. A qualified engineer he brings highly complementary skills to Nanopharm and enables the company to offer an integrated offering to partners. Nanopharm can now offer a suite of tailored services from early development of the active compound through clinical submissions, device design and prototyping and regulatory approval of both the drug and the device. Arron has experience in bringing a range of devices to market and this together with his rigour and discipline will make a significant contribution to the team.

Prof. Rob Price said “Arron’s appointment enables Nanopharm to provide an integrated approach to orally inhaled and nasal drug product development. Hitherto, device development and formulation optimisation are not typically integrated during the development cycle, which adds significant risk to OINDP programs. The combination of Nanopharm’s core strengths in material science, formulation development and device development, will de-risk and expedite product development programs of our growing client base.”

Dr Jag Shur said “Arron’s broader skills in project management will also provide us with industry leading standards and protocols as we continue to build our fee for service and co-development business. By combining device and formulation capabilities, Nanopharm aims to become the leading provider of integrated drug delivery solutions for OINDPs.”

About Nanopharm Ltd.

Nanopharm continues to make progress in building its business and team and anticipates making further announcements in due course. It operates out of a bespoke 6,000 square foot facility which has material characterisation capabilities, formulation development for DPIs, MDIs and nasal products and analytical labs to support development work. Critically Nanopharm also has its own proprietary API particle engineering technology, which it can use to develop bespoke particles for clients.

These services are under-pinned with a deep scientific knowledge in this area, honed over 20 years’, in which it can provide expertise in all areas of drug product development. As such it is fast becoming the “go to” group for complex problem solving and exquisite drug/device development.